Pharmaceuticals company Hester Biosciences announced Q4FY24 & FY24 results: Financial Highlights: Hester Biosciences reported an increase in standalone revenue by 20% and consolidated revenue by 18% in Q4FY24 compared to the previous year. The audited financial results for Q4 & FY24 show the company's resilience with a recommendation for a dividend of 6 per equity share of Rs 10 each (60%) for FY24, awaiting shareholder approval. The company has reduced its borrowing by 19% and increased cash generated from operations by 28% during the year. Overall gross profit margin in Q4FY24 increased by 1% compared to Q4FY23, primarily due to the increase in the proportion of vaccines from 60% to 75% in Q4FY24. In Q4FY24, EBITDA increased by 14% in alignment with a growth in sales, resulting in a 19% increase in PAT for the quarter. The total borrowings of the Company has reduced by Rs 307.58 million (19%) during the year. The cash generated from operations has increased by Rs 94.50 million (28%) during the year Animal Healthcare Division: The Animal Healthcare division saw a growth of 89% in Q4FY24, driven by sales of Goat Pox vaccine and vaccines for a government immunisation program. Despite regulatory challenges, the Animal Healthcare division has demonstrated the ability to recover and sustain growth. Poultry Healthcare Division: The Poultry Healthcare division achieved a notable growth of 22% in Q4FY24, with a consistent upward trend throughout the year. Strategic introductions of new products and leveraging market opportunities have been instrumental in the division's sales performance. Petcare Division: In Q4FY24, the Petcare division saw a minor decrease in sales from the previous quarter but reported a notable annual growth of 49%. The Petcare division's focus on building a strong foundation and delivering high-quality products is reflected in its substantial growth. Result PDF
Conference Call with Hester Biosciences Management and Analysts on Q3FY24 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Hester Biosciences announced Q2FY24 & H1FY24 results: 1. Financial Performance: Q2FY24: Revenue from Operations: Rs 704.55 crore, down 4% YoY EBITDA: Rs 132.12 crore, up 4% YoY Profit after Tax (excl. OCI): Rs 40.41 crore, down 39% YoY Earnings Per Share (EPS): Rs 4.75, down 39% YoY H1FY24: Revenue from Operations: Rs 1,583.08 crore, up 28% YoY EBITDA: Rs 275.75 crore, up 37% YoY Profit after Tax (excl. OCI): Rs 107.51 crore, up 6% YoY Earnings Per Share (EPS): Rs 12.64, up 6% YoY 2. Division Performance: - Animal Healthcare division experienced a 16% decline in sales in Q2FY24 due to uneven sales of the Goat Pox Vaccine. - Poultry Healthcare division saw a 4% decrease in overall sales in Q2FY24, with a growth in domestic vaccine sales, but a reduction in export sales. - Petcare division achieved impressive performance, growing 98% in Q2FY24. 3. Subsidiary Performance: - Hester Nepal had a turnover of Rs 7.28 million in Q2FY24, primarily from domestic sales of vaccines, with an overall net loss of Rs 7.05 million. - Hester Africa continued export sales but faced an overall loss of Rs 49.17 million due to foreign exchange fluctuations. - Hester's share of profit in the joint venture entity, Thrishool Exim Limited (Tanzania), increased by 9.86 million in Q2FY24. Result PDF
Conference Call with Hester Biosciences Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Hester Biosciences announced Q4FY23 & FY23 results: Standalone Q4FY23 & FY23: Overall gross profit margin reduced by 1% due to the change in product mix between vaccines and health products, health products sales having gone up. Operating EBITDA increased with the increase in sales. The reduction in EBITDA margin was due to the reduction in Gross Profit margin, accompanied by higher market development costs in animal health division and the new pet division Q4 PAT margin benefited from lower finance costs due to the reversal of unrealized forex loss of Rs 6.46 million on the translation of USD loan in Q4FY23, as against a loss of Rs 5.31 million in Q4FY22. Consequently, PAT increased by 27% from Rs 49.48 million to Rs 62.63 million. Result PDF